Effects of anti-epileptic drugs on spreading depolarization-induced epileptiform activity in mouse hippocampal slices

Ching-Huei Lin1,2, Shih-Pin Hsu3, Ting-Chun Cheng4, Chin-Wei Huang4, Yao-Chang Chiang5,6, I-Han Hsiao7, Ming-Hsueh Lee8, Mei-Lin Shen1,2, Dong Chuan Wu1,2 & Ning Zhou1,2

Epilepsy and spreading depolarization (SD) are both episodic brain disorders and often exist together in the same individual. In CA1 pyramidal neurons of mouse hippocampal slices, induction of SD evoked epileptiform activities, including the ictal-like bursts, which occurred during the repolarizing phase of SD, and the subsequent generation of paroxysmal depolarization shifts (PDSs), which are characterized by mild depolarization plateau with overriding spikes. The duration of the ictal-like activity was correlated with both the recovery time and the depolarization potential of SD, whereas the parameters of PDSs were not significantly correlated with the parameters of SD. Moreover, we systematically evaluated the effects of multiple anti-epileptic drugs (AEDs) on SD-induced epileptiform activity. Among the drugs that are known to inhibit voltage-gated sodium channels, carbamazepine, phenytoin, valproate, lamotrigine, and zonisamide reduced the frequency of PDSs and the overriding firing bursts in 20–25 min after the induction of SD. The GABA uptake inhibitor tiagabine exhibited moderate effects and partially limited the incidence of PDSs after SD. AEDs including gabapentin, levetiracetam, ethosuximide, felbamate, and vigabatrin, had no significant effect on SD-induced epileptic activity. Taken together, these results demonstrate the effects of AEDs on SD and the related epileptiform activity at the cellular level.

Spreading depolarization (SD, also called spreading depression) is a pathophysiological phenomenon that occurs under many neurological conditions, such as traumatic brain injury (TBI), aneurysmal subarachnoid hemorrhage (aSAH), intracerebral hemorrhage, and malignant cerebral infarction. SD is characterized by profound depolarization of neurons and glia, which is accompanied by massive ion exchange across plasma membranes of the affected cells. These electrical and ionic changes cause a disturbance in cell metabolism and might lead to cell death in metabolically compromised brain tissue. Interestingly, SD is highly associated with the development of epilepsy in patients with aSAH. In rodent and human brain slices, SD could trigger epileptiform responses that are characterized by ictal-like discharges on the tailing end of the extracellular potential shift of SD. After the membrane potential recovers from the depolarization resulting from the SD, the neuronal activity transforms into epileptic discharge patterns that are characterized by paroxysmal depolarization shifts (PDSs).

PDSs are considered to be the manifestation of epileptic interictal spikes at the level of single neurons. A PDS normally consists of a plateau-like depolarization associated with repetitive discharges of the neuron. The sustained depolarization is initiated by large excitatory postsynaptic potentials (EPSPs). The repetitive spikes...
are mediated by activation of voltage-gated Na⁺ channels (VGSCs). Activation of voltage-gated, high-threshold Ca²⁺ conductance and persistent Na⁺ conductance further contributes to the enhancement of depolarization. The repolarization phase of PDS is normally followed by hyperpolarization that involves a GABA,A receptor-mediated Cl⁻ conductance and Ca²⁺-dependent K⁺ conductance. A better understanding of the pharmacological sensitivity of SD-induced PDSs will have implications for the treatment of neurological conditions and complications that are associated with SD.

Anti-epileptic drugs (AEDs) include more than twenty molecular entities that are marketed worldwide. AEDs are effective by different mechanisms of action, including modulation of voltage-gated Na⁺ channels (VGSCs) and/or voltage-gated Ca²⁺ channels (VGCCs), enhancement of inhibitory synaptic transmission, or inhibition of excitatory neurotransmission. Activation of VGSCs is crucial for the generation of high-frequency repetitive discharges and PDSs, which are responsible for the generation of the ictal and interictal states of the seizure. High-voltage activated VGCCs (L-, P/Q-, N- and R-types) are required for presynaptic neurotransmitter release and might modulate neuronal firing patterns, whereas activation of low voltage-activated VGCCs (T-type) are involved in neuronal bursting. Moreover, some AEDs act at least partially by enhancing GABA transmission or inhibiting ionotropic glutamate receptors to modulate synaptic transmission. Different types of AEDs are used for the treatment of different classifications of seizures. However, which type of AEDs are most effective in preventing epileptiform activity induced by SD remains unknown.

In the present study, we systematically evaluated the inhibitory effects of AEDs on SD-induced epileptic activity. The effects of a range of existing AEDs, including carbamazepine, phenytoin, valproate, lamotrigine, zonisamide, felbamate, gabapentin, levetiracetam, ethosuximide, tiagabine and vigabatrin, were tested on the PDSs following SD induction in hippocampal CA1 pyramidal neurons of mouse brain slices.

**Results**

**SD induction of epileptiform activity.** Whole-cell patch clamp recordings were performed in the CA1 pyramidal neurons in mouse hippocampal slices. Under control conditions with physiological levels of extracellular K⁺ and Mg²⁺, prolonged epileptiform activity is rarely observed after SD. Previous studies have shown that SD could evoke long-lasting epileptiform activity in partially disinhibited slices, that is, using 1.25 mM bicuculline to partially block GABA,A receptors. This model is, however, not applicable to our study, since AEDs including tiagabine and vigabatrin mainly target on the GABAergic transmission. The network excitability could also be increased by inhibition of certain types of voltage-gated potassium channels with tetrodotoxin (TEA) or Cs⁺. Considering that bath application of potassium blockers will influence the propagating properties of SD, we tried intracellular application of Cs⁺ or TEA, which only modified the excitability of the recorded cell without affecting the propagation of SD or the excitability of the entire circuitry. Intracellular Cs⁺ increased the basal activities of neurons even without the induction of SD, causing a remarkable upshift of the resting membrane potential and massive spontaneous bursting; whereas intracellular TEA did not dramatically affecting the resting membrane potential or causing spontaneous epileptiform activity. Therefore, we tested whether SD could evoke epileptiform activity under a condition of 1.3 mM [Mg²⁺]₀, 5.0 mM [K⁺]₀, and internal TEA. In the current-clamp mode (I = 0), the resting membrane potentials of CA1 neurons were scattered between −52 mV to −62 mV in the recorded cells. Spontaneous neuronal firings with typical waveforms of single action potentials could be observed (Fig. 1A.). SD was induced by focal KCl ejection from a glass pipette according to a well-established protocol. The onset of SD was characterized by a profound depolarization of the membrane potential to −3.6 ± 1.0 mV with an averaged half-width duration of 35.8 ± 1.2 sec (n = 40) (Fig. 1A.). Such a depolarization phase represents a typical spreading depolarization as previously reported in human and animal models. High frequency spikes at a frequency of 1–5 Hz first appeared during the late repolarization phase of SD, which resembles the ictaform activity observed in spreading convulsions. The ictal-like activity normally started in the late phase of repolarization with a mean duration of 79.2 ± 4.3 sec (n = 40). After the membrane potentials recovered to baseline, another form of epileptiform activity that was characterized by PDSs developed from a pattern of broadened action potentials (Fig. 1A.). PDSs were characterized by mild but prolonged depolarization with overriding burst of spikes (Fig. 1A.). The occurrence of PDSs normally lasted over 30 min from the onset of SD. In a recording period of 20–25 min after the induction of SD, PDSs occurred at a mean frequency of 2.75 ± 0.34 times/min with an overriding burst of 6.18 ± 1.00 action potentials (Fig. 1B,C). These data indicate that SD induces PDSs that reflect epileptiform activity at the single cell level.

**Relationships among SD characteristics, SD-induced ictal-like activity, and PDSs.** As a first step towards a better understanding of the associations between SD and the epileptiform activity, we measured the 50% (τ₉₀) and 90% recovery time (τ₉₀) of SD, considering that the ictal-like activity normally started in the late repolarization phase of SD. τ₉₀ and τ₉₀ were determined by the duration from the time of the peak depolarization potential to the time at which the membrane potential reaches the 50% and 90% of full recovery, respectively. τ₀ was measured instead of the full recovery time because τ₀ is easier and more reliable to be defined. Our results showed that SD recovered with a mean τ₀ = 26.5 ± 1.1 sec and a mean τ₀ = 85.0 ± 5.4 sec (n = 40). The relationship between τ₀/τ₀ and other parameters of SD was assessed by two-tailed Pearson’s correlation analysis. The results show that τ₀ is highly correlated with the half-width duration of SD (Fig. 2A); interestingly, however, τ₀ has no significant correlation with the half-width duration (Fig. 2B). Furthermore, the peak depolarization potential was significantly correlated with τ₀ but not τ₀ (Fig. 2C,D). These data suggest that the time required for the near complete recovery was highly dependent upon the extent of membrane potential depolarization of the SD, whereas τ₀ is not directly associated with the depolarization potential.

Considering that the ictal-like activity unusually occurred during the late repolarization phase of SD, it would be interesting to examine its relationships to the SD depolarization potential and recovery time. The results showed that duration of the ictal-like activity was significantly correlated with τ₀ and the peak depolarization
potential of SD ($n = 40$, Fig. 3). These data suggest that higher extent of membrane depolarization likely facilitates a longer period of ictaliform events following SD.

Correlation analysis of the parameters of PDS showed that the number of PDSs and the number of spikes per PDS are significantly correlated ($n = 40$, Fig. 4A). However, the PDSs appeared to be independent from the ictal-like activity, since no significant correlation was found between the PDS parameters and the ictal duration (Fig. 4B,C). The PDS parameters did not exhibit any significant correlation with $\tau_{50}$, $\tau_{90}$, or the peak depolarization potential of SD, either (Fig. 4D–I). Taken together, these results indicate that the amplitude and recovery of SD have an influence on the following ictaliform activity rather than the later-generated PDSs.

**Influence of AEDs on the electrophysiological properties of the SD waveform.** Next, we tested the effects of a range of AEDs on SD parameters and SD-induced epileptiform activity. The tested AEDs include carbamazepine, phenytoin, valproate, lamotrigine, zonisamide, felbamate, gabapentin, levetiracetam,
Ethosuximide, tiagabine and vigabatrin. The concentration used for each compound was selected as medium to high doses according to previous in vitro studies (Table 1). We first examined whether the AEDs tested in our study have a direct modulatory effect on the electrophysiological parameters of SD. Table 2 summarizes $\tau_{50}$, $\tau_{90}$, and the peak depolarization potential after different AED treatments. Among the 11 tested AEDs, felbamate, tiagabine, and vigabatrin significantly increased $\tau_{50}$ of SD, suggesting that these drugs delay the early repolarization phase of SD (Table 2). However, when $\tau_{90}$ was measured, only felbamate and vigabatrin caused a significant increase. Treating with the other AEDs did not significantly change the $\tau_{90}$ of SD (Table 2). Moreover, phenytoin significantly suppressed the peak depolarization potential, whereas the other AEDs did not influence the extent of depolarization during SD (Table 2).

The anti-epileptic effects of older generation of AEDs that influence Na$^+$ channels. The first generation of AEDs are widely used in clinic due to their well-documented pharmacokinetics profiles. Among these drugs, carbamazepine, phenytoin, and valproate are known to prevent epilepsy by inhibition of VGSC activity. We first tested the effects of high concentrations of the three AEDs on SD-induced ictal duration and PDS parameters (Fig. 5). Our results show that 50 $\mu$M phenytoin significantly reduced the duration of ictiform discharges that occurred at the late repolarization phase of SD (28.7 ± 11.9 s, n = 6, p < 0.05 compared with control: 79.2 ± 4.3 s, n = 40), whereas carbamazepine (50 $\mu$M, 71.3 ± 18.7 s, n = 6, p = 0.97) or valproate (1 mM, 88.7 ± 10.3 s, n = 6, p = 0.83) did not show a significant effect. Next, we examined the effects of these AEDs on SD-induced PDSs. The three tested AEDs at high concentrations all potently inhibited the induction of PDSs after SD. There were no PDSs after treatment with carbamazepine (n = 6) or phenytoin (n = 6). Valproate strongly decreased frequency of PDSs (0.16 ± 0.07 times/min, n = 5, p < 0.001) and spike number per PDS (2.2 ± 1.0, n = 5, p = 0.13). Since high doses of carbamazepine and phenytoin showed a complete block on PDSs, we further tested if the lower concentrations of these AEDs were also effective. Our data showed that carbamazepine still completely blocked the generation of PDSs after SD at a concentration of 5 $\mu$M, but failed to produce a significant effect at 1 $\mu$M (1.3 ± 0.8 PDS/min for the frequency of PDSs, p = 0.70; and 3.2 ± 1.0 for the number of spikes/PDS, p = 0.43; n = 5). Phenytoin at a lower concentration of 5 $\mu$M still significantly inhibited the generation of PDSs after SD (0.04 ± 0.04 times/min for the frequency of PDSs, p < 0.001; and 0.6 ± 0.6 for the number of spikes/PDS, p < 0.001; n = 5). Taken together, these results indicate that carbamazepine, phenytoin, and valproate are effective in suppressing the SD-induced epileptiform activity.

**Figure 2.** Correlation of parameters of SD. Each point represents a pair of parameters of SD from a recorded neuron (n = 40). (A and B) The half-width durations of SD are significantly correlated with the $\tau_{50}$ (A) but not the $\tau_{90}$ (B) of SD. (C and D) The peak depolarization potential is not correlated with $\tau_{50}$ (C) but is rather correlated with the $\tau_{90}$ (D) of SD. $r^2$, R-squared from linear regression analysis; $p$, Pearson’s correlation coefficient; *P < 0.05; **P < 0.01.
Figure 3. Correlation of ictaform duration and parameters of SD. Each point represents a pair of ictaform duration and a parameter of SD from a recorded neuron (n = 40). The durations of ictal-like activity are significantly correlated with the $\tau_{50}$ (A), $\tau_{90}$ (B) and the peak depolarization potential of SD (C). $r^2$, R-squared from linear regression analysis; $\rho$, Pearson’s correlation coefficient; *$P < 0.05$; **$P < 0.01$.

Figure 4. Correlation of PDS parameters, ictaform durations, and parameters of SD. The PDS parameter, the ictaform duration, and the SD parameter from a recorded neuron are graphed in all pairwise combinations (n = 40). (A) The number of PDSs (as the total PDSs calculated in the 20-25 min after SD induction) is significantly correlated with the spike numbers during each PDS. (B and C) Neither the number of PDSs (B) or the number of spikes (C) is significantly with the duration of ictal-like duration. (D and F) There is no significant correlation between the number of PDSs and the parameters of SD. (G and I) There is no significant correlation between the spike number per PDS and the parameters of SD. $r^2$, R-squared from linear regression analysis; $\rho$, Pearson's correlation coefficient; *$P < 0.05$; **$P < 0.01$. 
The anti-epileptic effects of newer generation of AEDs that possibly influence Na\(^+\) channels.

The newer generation of AEDs has shown improved tolerability and safety. Among these drugs, lamotrigine, zonisamide, and felbamate have been reported to modulate VGCC-mediated neuronal responses\(^{26-28}\). Figure 6 summarizes the effects of these drugs on SD-induced epileptiform activity. Among the tested AEDs, only lamotrigine (60 μM; 25.1 ± 12.8 s, n = 5, p < 0.05) significantly inhibited the duration of SD-induced ictal-like discharges, whereas zonisamide (50 μM; 86.3 ± 13.0 s, n = 9, p = 0.95) or felbamate (100 μM; 115.7 ± 23.6 s, n = 8, p = 0.47) did not show a significant effect. Both lamotrigine and zonisamide significantly reduced the frequency of PDS generation after SD (0.12 ± 0.12, n = 5, p < 0.001 after treatment with lamotrigine; 0.04 ± 0.04, n = 9, p < 0.001 after treatment with zonisamide). The number of discharges during each PDS was also decreased after treatment with lamotrigine (0.8 ± 0.8, n = 5, p < 0.01) or zonisamide (0.4 ± 0.4, n = 9, p < 0.001). The treatment with 100 μM felbamate tended to influence the frequency of the PDSs (1.98 ± 0.80, n = 8, p = 0.81) or the spike numbers during the PDSs (4.01 ± 0.90, n = 8, p = 0.39). These data indicate that both lamotrigine and zonisamide effectively attenuated the SD-induced generation of PDSs, whereas felbamate had no significant effect.

Effects of AEDs that affects VGCCs. Gabapentin, levetiracetam, and ethosuximide are AEDs that are thought to mainly inhibit VGCCs. Gabapentin and levetiracetam mainly target the high-voltage activated Ca\(^{2+}\) channels\(^{29,30}\), while ethosuximide is a specific drug for absent seizures that works by blocking T-type VGCCs in the thalamus\(^{31}\). The duration of ictaliform discharges immediately following SD was not affected by gabapentin (50 μM; 78.3 ± 16.6 s, n = 5, p = 1.00), levetiracetam (100 μM; 62.2 ± 19.0 s, n = 5, p = 0.82), or ethosuximide (500 μM; 60.3 ± 18.1 s, n = 5, p = 0.75). The frequency of PDSs was 0.76 ± 0.62 time/min (n = 5, p = 0.10) after treatment with gabapentin, 5.24 ± 2.47 time/min (n = 5, p = 0.76) after levetiracetam, and 2.52 ± 0.94 time/min (n = 5, p = 0.99) after ethosuximide. The number of spikes per PDS was 3.92 ± 1.00 time/min (n = 5, p = 0.94) after levetiracetam, and 6.22 ± 0.80 time/min (n = 5, p = 1.00) after ethosuximide. Therefore, none of these AEDs induced a significant inhibition on either the ictaliform activity or the PDSs after SD (Fig. 7). These data suggest that SD-induced epileptiform activity is not sensitive to AEDs that modulate Ca\(^{2+}\) currents.

Effects of AEDs that modulate GABAergic transmission. The anticonvulsant actions of tiagabine and vigabatrin are mainly through the potentiation of GABAergic signaling. Tiagabine potentiates GABA-mediated synaptic responses by inhibiting GABA uptake transporters\(^{32}\). Vigabatrin is a GABA analogue that irreversibly inhibits GABA transaminase and increases the extracellular GABA concentration and tonic inhibition\(^{33}\). Our results showed that the duration of ictaliform activity was not affected by tiagabine (30 μM; 59.9 ± 19.6 s, n = 7, p = 0.63) or vigabatrin (200 μM, 64.5 ± 15.9 s, n = 6, p = 0.67). Tiagabine significantly reduced the number of PDSs (0.69 ± 0.50 time/min, n = 7, p < 0.05) and the spike number per PDS (1.98 ± 0.96, n = 7, p < 0.05). Vigabatrin produced a reducing trend on the frequency of PDSs (1.00 ± 0.62 time/min, n = 7); however, no statistical significant was reached for either PDS frequency (p = 0.08) or the number of spikes per PDS (3.80 ± 2.49, n = 7, p = 0.66) (Fig. 8). These results suggest that tiagabine rather than vigabatrin has an inhibitory effect on SD-induced PDSs.

Table 1. Clinical and in vitro doses for AEDs. aDoses for adults and children over 12 years of age. bDoses for adults. cDoses for adults and children over 14 years of age. dDoses for adults and children over 16 years of age. eThe optical dose for pediatric patients.  

| AED              | Dosage in human | Reported doses and mechanisms in vitro | Tested doses  |
|------------------|-----------------|---------------------------------------|--------------|
| Carbamazepine    | 200–1200 mg/day | Inhibits VGSCs with an IC\(_{50}\) of ~30 μM\(^{27}\) | 1, 5, and 50 μM |
| Phenytoin        | 300–600 mg/day  | Inhibits VGSCs with an IC\(_{50}\) of ~30 μM\(^{27}\) | 5 and 50 μM  |
| Valproate        | 10–60 mg/kg/day | Inhibits Na\(^+\) conductance and changes other parameters of Na\(^+\) currents at a concentration of 1 μM\(^{28}\) | 1 mM        |
| Lamotrigine      | 25–375 mg/kg/day | Inhibits human VGSCs with an IC\(_{50}\) of 56 μM\(^{20}\) | 60 μM        |
| Zonisamide       | 100–400 mg/day  | Enhances steady-state fast inactivation of Na\(^+\) current with a dissociation constant of 12 μM and reduces T-type Ca\(^{2+}\) current by 38% at 50 μM\(^{29}\) | 50 μM        |
| Felbamate        | 1200–3600 mg/day | Inhibits neuronal firing in striatal neurons with an IC\(_{50}\) of 28 μM and reduces NMDA-mediated currents by 29% at 100 μM\(^{30}\) | 100 μM       |
| Gabapentin       | 900–3600 mg/day | Inhibits VGCC-mediated currents with an IC\(_{50}\) of 167 nM and a saturated dose of 25 μM in DRG neurons\(^{34}\) | 50 μM        |
| Levetiracetam    | 1000–3000 mg/day | Inhibits VGCC-mediated currents with an IC\(_{50}\) of 14.7 μM in hippocampal neurons\(^{35}\) | 100 μM       |
| Ethosuximide     | 20 mg/kg/day    | Inhibits T-type VGCC-mediated currents with an IC\(_{50}\) of 50 μM\(^{26}\) | 500 μM       |
| Tiagabine        | 4–32 mg/day     | Prolongs the duration of IPSPs and inhibits epileptiform bursting at a concentration of 10 μM\(^{64}\) | 30 μM        |
| Vigabatrin       | 0.5–3 g/day     | Increased cellular GABA concentrations in slices and tonic GABA currents in cultured neurons at a concentration of 100 μM\(^{67}\) | 200 μM       |
Table 2. Effects of AEDs on parameters of SD. Data are presented as mean ± S.E.M. Significance differences were compared between the control group and the AED groups and were determined by a one-way ANOVA followed by two-tailed Dunnett-t post hoc test. *p < 0.05; **p < 0.01.

| AED        | Dose (μM) | n = (slices) | Animals | \(\tau_{50}\) (s) | P value | \(\tau_{90}\) (s) | P value | Peak potential (mV) | P value |
|------------|-----------|--------------|---------|---------------------|---------|---------------------|---------|---------------------|---------|
| Control    | —         | 40           | 40      | 26.5 ± 1.1          | —       | 85.0 ± 5.4          | —       | — ± 3.7             | 1.0     |
| Carbamazepine | 50       | 6            | 4       | 23.2 ± 1.4          | 0.59    | 88.7 ± 14.9         | 0.99    | — ± 6.2             | 2.3     | 0.81               |
| Phenytoin  | 50        | 6            | 5       | 21.2 ± 2.7          | 0.20    | 80.7 ± 13.2         | 0.99    | — ± 16.5            | 5.5     | 0.0006**            |
| Valproate  | 1000      | 6            | 5       | 32.7 ± 3.2          | 0.11    | 105.8 ± 22.1        | 0.48    | — ± 6.3             | 3.2     | 0.79               |
| Lamotrigine | 60        | 5            | 4       | 20.4 ± 5.1          | 0.37    | 69.1 ± 23.9         | 0.71    | — ± 8.7             | 2.7     | 0.33               |
| Zonisamide | 50        | 9            | 8       | 27.4 ± 3.0          | 0.99    | 79.0 ± 10.1         | 0.95    | — ± 5.6             | 2.8     | 0.81               |
| Felbamate  | 100       | 8            | 5       | 49.6 ± 5.1          | 0.0003**| 121.0 ± 12.4        | 0.03*   | — ± 8.2             | 3.1     | 0.26               |
| Gabapentin | 50        | 5            | 3       | 28.9 ± 7.1          | 0.93    | 66.9 ± 12.1         | 0.66    | — ± 2.0             | 3.3     | 0.93               |
| Levetiracetam | 100      | 5            | 4       | 23.5 ± 6.9          | 0.87    | 76.4 ± 29.2         | 0.94    | — ± 5.4             | 2.9     | 0.90               |
| Ethosuximide | 500      | 5            | 5       | 26.3 ± 6.1          | 1.00    | 59.1 ± 14.0         | 0.36    | — ± 9.6             | 2.4     | 0.15               |
| Tiagabine  | 30        | 7            | 4       | 45.7 ± 4.7          | 2.0e-6**| 87.5 ± 12.1         | 0.98    | — ± 4.8             | 2.5     | 0.87               |
| Lamotrigine | 60        | 5            | 4       | 20.4 ± 5.1          | 0.37    | 69.1 ± 23.9         | 0.71    | — ± 8.7             | 2.7     | 0.33               |
| Zonisamide | 50        | 9            | 8       | 27.4 ± 3.0          | 0.99    | 79.0 ± 10.1         | 0.95    | — ± 5.6             | 2.8     | 0.81               |
| Felbamate  | 100       | 8            | 5       | 40.6 ± 5.1          | 0.0003**| 121.0 ± 12.4        | 0.03*   | — ± 8.2             | 3.1     | 0.26               |
| Gabapentin | 50        | 5            | 3       | 28.9 ± 7.1          | 0.93    | 66.9 ± 12.1         | 0.66    | — ± 2.0             | 3.3     | 0.93               |
| Levetiracetam | 100      | 5            | 4       | 23.5 ± 6.9          | 0.87    | 76.4 ± 29.2         | 0.94    | — ± 5.4             | 2.9     | 0.90               |
| Ethosuximide | 500      | 5            | 5       | 26.3 ± 6.1          | 1.00    | 59.1 ± 14.0         | 0.36    | — ± 9.6             | 2.4     | 0.15               |
| Tiagabine  | 30        | 7            | 4       | 45.7 ± 4.7          | 2.0e-6**| 87.5 ± 12.1         | 0.98    | — ± 4.8             | 2.5     | 0.87               |
| Valproate  | 1000      | 6            | 5       | 32.7 ± 3.2          | 0.11    | 105.8 ± 22.1        | 0.48    | — ± 6.3             | 3.2     | 0.79               |

Figure 5. The effects of carbamazepine, phenytoin, and valproate on SD-induced epileptiform activity. (A) Representative traces showing the changes in the membrane potential after treatment with carbamazepine (50 μM), phenytoin (50 μM), or valproate (1 mM). (B) Quantitative results showing the effects of AEDs on the duration of ictal-like activity. (C) Quantitative results showing the frequency of PDSs after treatment with carbamazepine (1–50 μM), phenytoin (5–50 μM), or valproate (1 mM) than in control. (D) Quantitative results showing the number of spikes per PDS after treatment with carbamazepine (1–50 μM), phenytoin (5–50 μM), or valproate (1 mM) than in control. Significance differences were determined by a One-way ANOVA with the Games-Howell post hoc test and were defined as *P < 0.05; **P < 0.01; ***P < 0.001.
Discussion

SD and epilepsy are both episodic disorders caused by brain hyperexcitation or damage. They share many clinical features as well as some underlying mechanisms and could co-occur in the cerebral cortex. In rat hippocampal slices, both SD and epilepsy could be induced by repetitive stimulation, especially under conditions of low extracellular Mg concentrations. In human slices, SD enhanced the repetition rate and amplitude of spontaneous seizure-like activity. Instances of both SD and epilepsy implicated the role of ionotropic glutamate receptors. Moreover, the results from clinical studies suggest that the occurrence of seizures is highly associated with SD after acute brain injury. The ictal epileptic field potentials in particularly could start at the end of the potential change of SD in aSAH patients. Epilepsy is a well-recognized complication that occurs after acute brain injuries, especially including hemorrhagic stroke and TBI. Many types of AEDs have been used as prophylaxis to prevent the onset of seizures and late seizures after brain injury conditions. For example, phenytoin, carbamazepine and valproate are traditionally used as the primary choice of prophylactic drugs after aSAH; newer AEDs, such as levetiracetam, lamotrigine, gabapentin, and zonisamide, have also been used because of their better side effect profiles. However, the effects of these AEDs are uncertain due to the lack of randomized and placebo controlled trials. The mechanisms of epileptogenesis after brain injury also remain largely unclear. Some studies have demonstrated that one contributing factor is the disruption of the blood-brain barrier after these conditions. Functional changes in astrocytes could also enhance hyperexcitability and hyper-synchronization.
among neurons. The alterations in the blood-brain barrier and glial cells could be further aggravated by epilepsy and SD. Moreover, electrocorticography (ECoG) recordings showing that SD precedes ictal discharges in some aSAH patients suggest that SD could directly or indirectly increase the susceptibility to seizures under the condition of brain damage. Effective attenuation of epileptiform activity after SD may help to reduce seizures in these patients.

In the present study, we showed that epileptiform activity could be induced by SD under a condition of increased neuronal excitability, since internal TEA could enhance EPSP, increase membrane input resistance, and produce a slight membrane depolarization. Under these conditions, SD first induced a phase of ictal-like events that occurred at the late repolarization phase. The duration of the ictal-like discharges are significantly correlated with \( \tau_{50} \) and the peak potentiation potential of SD, suggesting that a longer recovery time and a more depolarized state of SD favors the occurrence of ictal-like activity. In the present model, SD also induced a prolonged phase of interictal-like activity, which was shown as the PDSs. SD-induced PDSs have also been observed in previous studies, in which PDS persisted for ~1 h in rat neocortical and hippocampal slices under a condition of 1.25 \( \mu \)M bicuculline that leads to partial disinhibition. However, the mechanism for the generation of PDSs remains unknown. Our results showed that the parameters of PDSs, including the frequency and spike numbers per PDS, were not significantly correlated with the parameters of SD or the parameter of ictal-like activity. It is possible that the SD-triggered strong ionic and metabolic responses disrupt the balance between neural excitation and inhibition. Under a condition of partial disinhibition, PDSs could be evoked when SD nudges this balance towards hyper-excitation.

Carbamazepine, phenytoin, lamotrigine, valproate, and zonisamide are potent VGSC inhibitors. These AEDs block high-frequency repetitive spike discharges without significantly affecting physiological action potentials. In this study, carbamazepine, phenytoin, lamotrigine, valproate, and zonisamide reduced not only the number of overriding action potentials during the PDS but also the incidence of PDSs after SD. This could be due to multiple

**Figure 7.** The effects of gabapentin, levetiracetam, and ethosuximide on SD-induced epileptiform activity. (A) Representative traces showing the changes in the membrane potential after treatment with gabapentin (50 \( \mu \)M), levetiracetam (100 \( \mu \)M), and ethosuximide (500 \( \mu \)M). (B) Quantitative results showing the effects of AEDs on the duration of ictal-like activity. (C) Quantitative results showing the frequency of PDSs after treatment with gabapentin (50 \( \mu \)M), levetiracetam (100 \( \mu \)M), and ethosuximide (500 \( \mu \)M) compared to that of control. (D) Quantitative results showing the number of spikes per PDS after treatment with gabapentin (50 \( \mu \)M), levetiracetam (100 \( \mu \)M), and ethosuximide (500 \( \mu \)M) compared to that of control. Significance differences were determined by a One-way ANOVA with the Games-Howell post hoc test and were defined as *P < 0.05; **P < 0.01; ***P < 0.001.
mechanisms of actions of these AEDs. First, VGSC-targeting AEDs, such as phenytoin and lamotrigine, produce a tonic inhibition on VGSCs by voltage-dependent and use-dependent manners\(^2\). They preferentially bind to the inactivated conformation of the channel and exhibited stronger inhibition when the depolarization state was prolonged and accumulated\(^2\). During the PDSs, the prolonged depolarization of the neuronal membrane causes repetitive discharges, which are sensitive to AED blockade\(^1\). Second, the binding and unbinding kinetics of these AEDs are slow\(^5\). In our experiments, the onset of SD is accompanied by a sustained depolarization of the membrane potential that reaches ~0 mV and lasts for tens of seconds. Such a condition already favors the binding of AEDs and therefore prevents the generation of PDSs. Third, some AEDs might also inhibit the persistent Na\(^+\) currents. Persistent Na\(^+\) currents contribute to the initiation and enhancement of PDSs when the PDS is induced by an EPSP\(^1\). Therefore, inhibition of persistent Na\(^+\) currents could reduce the extent of depolarization during the PDS. Together, these properties of VGSC-targeting AEDs might contribute to the suppression of both the incidence of PDSs and the overriding discharges induced by SD.

We also tested VGCC-targeting AEDs including gabapentin, levetiracetam, and ethosuximide, for their ability to affect epileptiform activity after SD. Blocking Ca\(^{2+}\) channels could inhibit the release of neurotransmitters and attenuate postsynaptic excitability\(^3\). Gabapentin and levetiracetam are thought to modulate high voltage-activated Ca\(^{2+}\) channels, whereas ethosuximide mainly inhibits T-type Ca\(^{2+}\) channels. However, the pharmacological mechanisms of these AEDs are complex. For example, levetiracetam is known to modulate N-type Ca\(^{2+}\) channels\(^3\), and it also binds to the synaptic vesicle protein SV2A to modulate neurotransmitter release and stabilizes GABA\(_A/\) receptors to facilitate inhibition\(^4\). In our study, gabapentin, levetiracetam, and ethosuximide did not show significant inhibition of the generation of PDSs, suggesting that SD-induced epileptiform activity was relatively insensitive to this type of AED. In a previous study, however, levetiracetam could reduce the duration and depolarization magnitude of PDSs induced by Mg\(^{2+}\)-free solutions containing 4-aminopyridine.

**Figure 8.** The effects of tiagabine and vigabatrin on SD-induced epileptiform activity. (A) Representative traces showing the changes in the membrane potential after treatment with tiagabine (30 μM) and vigabatrin (200 μM). (B) Quantitative results showing the effects of AEDs on the duration of ictal-like activity. (C) Quantitative results showing the frequency of PDSs after treatment with tiagabine (30 μM) and vigabatrin (200 μM) compared to that of control. (D) Quantitative results showing the number spikes per PDS after treatment with tiagabine (30 μM) and vigabatrin (200 μM) compared to that of control. Significance differences were determined by a One-way ANOVA with the Games-Howell post hoc test and were defined as *P < 0.05; **P < 0.01; ***P < 0.001.
and bicuculline. This could largely result from the difference in the condition of the induction of epilepsy: in the study by Piscitelli et al., GABAergic transmission was blocked and NMDA receptors were potentiated. Such a condition could be more favorable to the generation of PDSs that are initiated by the largely enhanced excitatory synaptic transmission. The increased synaptic release and the resulting PDSs therefore largely depend on activation of VGCCs and are sensitive to levetiracetam.

The GABAergic transmission is also involved in the SD-induced epileptiform activity. The slices are more susceptible to generate epilepsy after SD when low concentrations of GABA receptor antagonists were applied. It has been reported that SD causes changes in receptor binding sites of both glutamate and GABA receptors and leads to an imbalance between excitatory and inhibitory inputs during the late phase. The spontaneous and miniature inhibitory postsynaptic currents exhibited decreased frequency and increased amplitude after SD. Therefore, the altered GABAergic transmission might contribute to epileptogenesis after SD. In this study, we show that the frequency of PDSs induced by SD was reduced by tiagabine. Tiagabine is a potent and selective inhibitor of the GABA uptake transporter GAT1, which is responsible for removing GABA from the synaptic cleft. Tiagabine can slow the reuptake of GABA from synapses and prolong the inhibitory postsynaptic potential. Our results suggest that enhancing GABA inhibition might attenuate SD-induced epileptiform activity.

In conclusion, our study reveals that AEDs that mainly target VGCCs, including carbamazepine, phenytoin, valproate, lamotrigine, and zonisamide, are potent inhibitors of SD-induced epileptiform activity. Tiagabine, which mainly modulates GABAergic transmission, also exhibits moderate inhibitory effects. AEDs that inhibit VGCCs, including gabapentin, levetiracetam, and ethosuximide, do not significantly affect the generation of PDSs after SD. These data will have implications for the therapy of epilepsy as a complication of SD-related neurological disorders.

Methods

Preparation of brain slices. All experimental procedures were in accordance with the Institutional Guidelines of China Medical University for the Care and Use of Experimental Animals (IACU-M-CUEA) and were approved by the Institutional Animal Care and Use Committee (IACUC) of China Medical University. Hippocampal slices were prepared from 12 to 21-day-old ICR mice of either sex. Mice were anesthetized with urethane and decapitated. Brains were removed and placed in ice-cold artificial cerebrospinal fluid (ACSF) containing the following (in mM): 126 NaCl, 2.5 KCl, 2.0 MgCl2, 1.25 NaH2PO4, 26 NaHCO3, and 10 D-glucose. Then, 350 μm-thick transverse hemi-sections from the hippocampus were sliced (Leica vibratome). The slices were incubated at room temperature for 1 h before recording. The slices were then transferred to the recording chamber with fresh ACSF containing the following (in mM): 125 NaCl, 5.0 KCl, 1.3 MgCl2, 2.0 CaCl2, 1.25 NaH2PO4, 26 NaHCO3, and 10 D-glucose. All solutions were saturated with 95% O2/5% CO2. In all pharmacological experiments, slices were pre-treated with chemicals for 20 min before SD induction unless specifically mentioned otherwise.

Whole-cell patch clamp recordings. Whole-cell patch clamp recordings were performed in CA1 pyramidal neurons using a MultiClamp 700B amplifier. The membrane potential was acquired under current-clamp mode without any holding current applied (I = 0 mode). Patch electrodes (3–7 MΩ) were pulled from 1.5-mm outer diameter thin-walled glass capillaries in three stages and were filled with intracellular solutions containing the following (in mM): 98 K-gluconate, 17 KCl, 10 HEPES, 1.1 EGTA, 0.1 CaCl2, 25 TEA-Cl, and 2 Na2-ATP, pH 7.25, osmolarity 290–300. Input resistance was obtained before and after each recording and recordings with a >25% change in input resistance were discarded. Signals were acquired via a Digidata 1440 A analog-to-digital interface and were low-pass filtered at 2 kHz and digitized at 10 kHz.

Induction and acquisition of SD and SD-associated epileptiform activity. Individual slices were transferred to a recording chamber (Fast Exchange Diamond Bath Chamber from Warner Instruments, Hamden, CT, USA) perfused with oxygenated ACSF at room temperature. SD was induced with a brief focal ejection of 2.5 M KCl from a glass pipette (resistance ~1–3 MΩ). The puffing pipette was placed close to the surface of the CT, USA) perfused with oxygenated ACSF at room temperature. SD was induced with a brief focal ejection of 2.5 M KCl from a glass pipette (resistance ~1–3 MΩ). The puffing pipette was placed close to the surface of the slice (z < 5 μm) in the CA3 stratum radiatum. Whole-cell recordings were made from CA1 pyramidal neurons at locations >200 μm from the KCl ejection site. One neuron was recorded in each slice, and a fresh slice was used for each new trial. The onset of SD was indicated by the well-established electrophysiological criteria for an SD: abruptly developing depolarization of neuronal membrane potential to nearly 0 mV. Under a condition of 1.3 mM extracellular Mg2+ , 5.0 mM extracellular K+ and intracellular TEA that helps to enhance excitability of the recorded neuron, intensive ictal-like activity occur in the repolarizing phase of SD. The peak depolarization potential was measured as the highest value of the absolute membrane potential reached during the SD. The half-width duration of the SD was measured at the half-maximum of the potential shifts. The SD was determined by measuring the time intervals from the peak depolarization potential to the point where membrane potential returns to 50% and 90% of resting membrane potentials, respectively. The duration of ictal-like activity was measured by the duration of continuous bursts (1–5 Hz) that occurred during the repolarization phase of SD. PDSs normally appeared after the ictal-like activity had stopped and were identified by a prolonged depolarization plateau with overriding repetitive discharges (> = 3) with a frequency of > = 5 Hz. Depolarization shifts with 2 spikes (and less) may represent the physiological firing pattern of “early-bursting pyramidal neurons” and thereby were not considered as PDSs. The frequency of PDSs was calculated at times/min. The spike number was calculated as the number of repetitive spikes during each PDS. If there was no PDS occurred, the frequency of PDS and spike number/PDS were both considered 0. The frequency of PDS and spike number were analyzed as a mean value each min during the 20–25 min after the onset of SD in Figs 5–8.
Chemicals. Phenytoin, levetiracetam, ethosuximide, and tiagabine were obtained from Sigma-Aldrich (St. Louis, MO, USA). Carbamazepine, valproate, lamotrigine, zonisamide, felbamate, gabapentin, and vigabatrin were obtained from Tocris (Avonmouth, Bristol, UK).

Data analysis. Data in all figures are reported as the mean ± standard error of mean (s.e.m.). Statistical analysis was performed using the Statistical Product and Service Solutions (SPSS, IBM). One-way analysis of variance with the Games-Howell post hoc test or the two-tailed Dunnett-t post hoc test was used for statistical comparisons of multiple groups. Pearson's correlation coefficient (p) was used for correlation analysis. Statistical significance was defined as *p < 0.05; **p < 0.01; ***p < 0.001.

References
1. Lauritzen, M. et al. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. J Cereb Blood Flow Metab 31, 17–35 (2011).
2. Dreier, J. P. et al. Recording, analysis, and interpretation of spreading depolarizations in neurointensive care: Review and recommendations of the COSBID research group. J Cereb Blood Flow Metab 37, 1595–1625 (2017).
3. Somjen, G. G. Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiol Rev 81, 1065–1096 (2001).
4. Hartings, J. A. et al. The continuum of spreading depolarizations in acute cortical lesion development: Examining Leao's legacy. J Cereb Blood Flow Metab (2016).
5. Dreier, J. P. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med 17, 439–447 (2011).
6. Dreier, J. P. et al. Spreading convulsions, spreading depolarization and epileptogenesis in human cerebral cortex. Brain 135, 259–275 (2012).
7. Van Harreveld, A. & Stamm, J. S. Spreading cortical convulsions and depressions. J Neurophysiol 16, 352–366 (1953).
8. Eickhoff, M. et al. Spreading depression triggers icteriform activity in partially disinfibulated neauronal tissues. Exp Neurol 253, 1–15 (2014).
9. McCormick, D. A. & Contreras, D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol 63, 815–846 (2001).
10. Johnston, D. & Brown, T. H. Giant synaptic potential hypothesis for epileptiform activity. Science 211, 294–297 (1981).
11. Timofeev, I., Grenier, F. & Steriade, M. Contribution of intrinsic neuronal factors in the generation of cortically driven electrographic seizures. J Neurophysiol 92, 1133–1144 (2004).
12. Rogawski, M. A. & Loscher, W. The neurobiology of antiepileptic drugs. J Biol Chem 289, 25319–25323 (2014).
13. Willow, M., Gonoi, T. & Catterall, W. A. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on neuronal sodium channels. Pflugers Arch 438, 883–892 (2000).
14. Mantegazzza, M., Curia, G., Biagini, G., Ragsdale, D. S. & Avoli, M. Voltage-gated sodium channels as therapeutic targets in epilepsy. Eur J Pharmacol 604, 50–56 (2010).
15. Aitken, P. G., Jing, J., Young, J. & Somjen, G. G. Ion channel involvement in hypoxia-induced spreading depression in hippocampal slices. Brain Res 541, 7–11 (1991).
16. Atkerson, R. G. & Avoli, M. Voltage-gated sodium channels and therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 9, 127–142 (2010).
17. Timofeev, I., Grenier, F. & Steriade, M. Contribution of intrinsic neuronal factors in the generation of cortically driven electrographic seizures. J Neurophysiol 92, 1133–1144 (2004).
18. Aitken, P. G., Jing, J., Young, J. & Somjen, G. G. Ion channel involvement in hypoxia-induced spreading depression in hippocampal slices. Brain Res 541, 7–11 (1991).
19. Ayata, C. Pearls and pitfalls in experimental models of spreading depression. Cephalalgia 33, 604–613 (2013).
20. Aiba, I. & Shuttleworth, C. W. Sustained NMDA receptor activation by spreading depolarizations can initiate excitotoxic injury in metabolically compromised neurons. J Physiol 590, 5879–5893 (2012).
21. Gorji, A. et al. Spreading depression in human neocortical slices. Brain Res 906, 74–83 (2001).
22. Ragsdale, D. S., Scheuer, T. & Catterall, W. A. Frequency and voltage-dependent inhibition of type IIA Na+ channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Mol Pharmacol 40, 756–765 (1991).
23. Heuer, A. & De Biase, D., Barra, D., Bossa, F., Pucci, P. & John, R. A. Chemistry of the inactivation of 4-aminobutyrate aminotransferase by the antiepileptic drug vigabatrin. J Biol Chem 266, 20056–20061 (1991).
24. Rogawski, M. A. In Jasper’s Basic Mechanisms of the Epilepsies (eds J. L. Noebels et al.) (Oxford, 2012).
25. Koreleva, V. I. & Bures, J. Cortical penicillin focus as a generator of repetitive spike-triggered waves of spreading depression in rats. Exp Brain Res 51, 291–297 (1983).
26. Mody, I., Lambert, J. D. & Heinemann, U. Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices. J Neurophysiol 57, 869–888 (1987).
39. Gilmore, E., Choi, H. A., Hirsch, L. J. & Claassen, J. Seizures and CNS hemorrhage: spontaneous intracerebral and aneurysmal subarachnoid hemorrhage. *Neurocrit Care* 16, 165–175 (2010).

40. Pitkanen, A. *et al.* Posttraumatic epilepsy - disease or comorbidity? *Epilepsia* 58, 19–24 (2014).

41. Marigold, R., Gunther, A., Tiwari, D. & Kwan, J. Antiepileptic drugs for the primary and secondary prevention of seizures after subarachnoid haemorrhage. *Cochrane Database Syst Rev* 6, CD008710 (2013).

42. Shlosberg, D., Benilfa, M., Kaufe, D. & Friedman, A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. *Nat Rev Neurol* 6, 393–403 (2010).

43. Robel, S. *et al.* Reactive astrogliaosis causes the development of spontaneous seizures. *J Neurosci* 35, 3330–3345 (2015).

44. Lapilover, E. *et al.* Peri-infarct blood-brain barrier dysfunction facilitates induction of spreading depolarization associated with epileptiform discharges. *Neurobiol Dis* 48, 495–506 (2012).

45. Wetherington, J., Serrano, G. & Dungledine, R. Astrocytes in the epileptic brain. *Neuron* 58, 168–178 (2008).

46. Pito, C. K., Schaefer, J. A. & Plum, F. Ultrastructural characteristics of the brain and blood-brain barrier in experimental seizures. *Brain Res* 127, 251–267 (1977).

47. Nowak, L. M. & Macdonald, R. L. Substance P: ionic basis for depolarizing responses of mouse spinal cord neurons in cell culture. *J Neurosci* 2, 1119–1128 (1982).

48. Clements, J. D., Nelson, P. G. & Redman, S. J. Intracellular tetraethylammonium ions enhance group IIA excitatory post-synaptic potentials evoked in cat motoneurons. *J Physiol* 377, 267–282 (1986).

49. Xie, X., Lancaster, B., Peakman, T. & Garthwaite, J. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na + channels and with native Na + channels in rat hippocampal neurons. *Epilepsia* 430, 437–446 (1995).

50. Matsu, N., Quandt, F. N., Ten Eick, R. E. & Yeh, J. Z. Characterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells. *J Pharmacol Exp Ther* 228, 523–530 (1984).

51. Kuo, C. C. & Bean, B. P. Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. *Mol Pharmacol* 46, 716–725 (1994).

52. Kuo, C. C. & Lu, L. Characterization of lamotrigine inhibition of Na + channels in rat hippocampal neurons. *Br J Pharmacol* 121, 1231–1238 (1997).

53. Timofeeva, I., Bazhenov, M., Sejnowski, T. & Steriade, M. Cortical hyperpolarization-activated depolarizing current takes part in the generation of focal paroxysmal activities. *Proc Natl Acad Sci USA* 99, 9533–9537 (2002).

54. Zamponi, G. W. Targeting voltage-gated calcium channels in neurological and psychiatric diseases. *Nat Rev Drug Discov* 15, 19–34 (2016).

55. Lynch, B. A. *et al.* The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. *Proc Natl Acad Sci USA* 101, 9861–9866 (2004).

56. Palma, E. *et al.* The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation. *Epilepsia* 48, 1842–1849 (2007).

57. Pisani, A. *et al.* Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. *Epilepsia* 45, 719–728 (2004).

58. Haghiri, H., Kovac, S., Speckmann, E. J., Zilles, K. & Gorji, A. Patterns of neurotransmitter receptor distributions following cortical spreading depression. *Neuroscience* 163, 1340–1352 (2009).

59. Aiba, I. & Shuttleworth, C. W. Characterization of inhibitory GABA-A receptor activation during spreading depolarization in brain slice. *PLoS One* 9, e110849 (2014).

60. Sawant-Pokam, P. M., Suryavanshi, P., Mendez, J. M., Dudek, F. E. & Brennan, K. C. Mechanisms of Neuronal Silencing After Cortical Spreading Depression. *Cereb Cortex* 27, 1311–1325 (2017).

61. Collie, H. & Harreved, A. V. Membrane potential of cerebral cortical cells during reading depression and asystia. *Exp Neurol* 15, 425–436 (1966).

62. Graves, A. R. *et al.* Hippocampal pyramidal neurons comprise two distinct cell types that are countermodulated by metabotropic receptors. *Neuron* 76, 776–789 (2012).

63. Goldenberg, M. M. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. *P T* 35, 392–415 (2010).

64. Kito, M., Maehara, M. & Watanabe, K. Mechanisms of T-type calcium channel blockade by zonisamide. *Seizure* 5, 115–119 (1996).

65. Pisani, A. *et al.* Electrophysiological actions of felbamate on rat striatal neurons. *Br J Pharmacol* 116, 2053–2061 (1995).

66. Sutton, K. G., Martin, D. J., Pinnock, R. D., Lee, K. & Scott, R. H. Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurons. *Br J Pharmacol* 135, 257–265 (2002).

67. Niespodziany, I., Klitgaard, H. & Margineanu, D. G. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurons of rat hippocampal slices. *Neurosci Lett* 360, 5–8 (2001).

68. Gomora, J. C., Daud, A. N., Weiergraber, M. & Perez-Reyes, E. Block of cloned human T-type calcium channels by succinimidine antiepileptic drugs. *Mol Pharmacol* 69, 1121–1132 (2001).

69. Thompson, S. M. & Gahwiler, B. H. Effects of the GABA uptake inhibitor tiagabine on inhibitory synaptic potentials in rat hippocampal slice cultures. *J Neurophysiol* 67, 1689–1701 (1992).

70. Errante, L. D., Williamson, A., Spencer, D. D. & Petroff, O. A. Gabapentin and vigabatrin increase GABA in the human neocortical slice. *Epilepsy Res* 49, 203–210 (2002).

71. Wu, Y., Wang, W. & Richerson, G. B. Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release. *J Neurophysiol* 89, 2021–2034 (2003).

Acknowledgements

This study was supported by grants from the Ministry of Science and Technology (MOST 101-2320-B-039-003, MOST 104-2320-B-039-045-MY3, MOST 104-2320-B-039-048-MY3, MOST 106-2314-B-006-003, MOST 106-2320-B-006-055, and MOST 105-2632-B-039-002), China Medical University Hospital (DMR-106-170) and I-Da Hospital (NCKUEDA 10405), and in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center (MOHW105-TDU-B-212-133019).

Author Contributions

S.-PH., C.-WH., D.C.W. and N.Z. designed the study and coordinated the project, C.-H.L., T.-C.C. and M.-L.S. carried out the experiments, C.-H.L., S.-PH., T.-C.C. and M.-H.L. analyzed data, Y.-C.C. and I.-H.H. contributed to slice preparation, C.-WH., D.C.W. and N.Z. wrote the manuscript with the input of remaining authors.

Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
